Zacks.com on MSN2d
Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU
Pfizer PFE announced that the European Commission (“EC”) has granted marketing authorization for Hympavzi (marstacimab) to ...
Outsourcing-pharma2d
Pfizer’s HYMPAVZI for Hemophilia A or B receives EU approval
The European Commission has approved Pfizer’s treatment for adults and adolescents with severe hemophilia A or B.
Armed robbery in Revesby2d
EU Greenlights Pfizer's HYMPAVZI for Severe Hemophilia
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for HYMPAVZI™ (marstacimab) for the ...
The Pharma Letter2d
EC approval for Pfizer’s Hympavzi
The European Commission (EC) has granted marketing authorization for Hympavzi (marstacimab), from US pharma giant Pfizer. The ...
Pharmabiz2d
Pfizer’s Hympavzi receives European marketing approval to treat adults and adolescents with severe haemophilia A or B without inhibitors
Pfizer’s Hympavzi receives European marketing approval to treat adults and adolescents with severe haemophilia A or B without inhibitors: New York Thursday, November 21, 2024, 0 ...
pharmaphorum3d
Pfizer bags EU okay for haemophilia drug Hympavzi
Pfizer's Hympavzi has become the first once-weekly subcutaneous treatment for people living with severe haemophilia B in the EU that can be delivered via an autoinjector device at home.
Pfizer announces EC approval for Hympavzi
Pfizer (PFE) announced that the European Commission, or EC, has granted marketing authorization for Hympavzi for the routine prophylaxis of ...